Skip to main content

New risk factor for leukoencephalopathy Progressive multifocal (PML) associated with Tysabri (natalizumab)


The Food and Drug Administration (FDA) and inform the public that have been identified to test positive for antibodies against JC (JCV) as a risk factor for HIV leukoencephalopathy progressive multifocal (PML). PML is an inflammation of the brain are rare but serious associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis (MS) or Crohn's disease.
It should be that the risks and benefits of continuing treatment with Tysabri be carefully considered in patients who are found to be anti-JCV antibodies of the positive and you have one or more of the other risk factors known to the PML. Patients who suffer from all the three known risk factors have estimated the risk of PML of 11/1 for users, 000. Risk factors are:The presence of antibodies against JCV.Longer duration of treatment Tysabri, especially after 2 years.Before treatment with immunosuppressive drugs (for example, mitoxantrone, azathioprine, methotrexate, cyclophosphamide, or inhibition mofetil).
Has been revised drug label for Tysabri to reflect this updated information including the schedule of estimating the rate of PML stratified by three known risk factors.
Can determine the status of the patient's antibodies to anti-JCV antibody detection using the anti-JCV test that has been verified analytically and clinically, and ordered by a physician. JCV was cleared applied body ELISA test by the FDA on January 20, 2012.Test positive for anti-JCV antibodies means that a person is exposed to JCV in the past
Labels:

Comments

  1. Anonymous16 April 2012 at 14:27

    This is going to be a conclusive test for MS patients opting for Tysabri as treatment. In case the patients is tested positive certain measures should be taken:
    -closer monitoring for any signs of PML;
    -decrease the time between MRI scans.
    The doctors treating patients more susceptible to PML should be prepared to offer progressive multifocal leukoencephalopathy treatments as fast as possible.

    ReplyDelete

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more